Hepatic Mitochondria-Gut Microbiota Interactions in Metabolism-Associated Fatty Liver Disease

Area of Science:

• Hepatology
• Microbiology
• Mitochondrial Biology

Background:

• Metabolism-associated fatty liver disease (MAFLD) is a growing global health concern with significant morbidity and mortality risks.
• Gut microbiota dysbiosis is increasingly recognized as a key factor in MAFLD development and progression.
• The gut microbiota influences liver health through metabolic pathways, immune modulation, and inflammatory signaling.

Purpose of the Study:

• To review the role of gut microbiota and its metabolites in MAFLD.
• To elucidate the interplay between gut microbiota and liver mitochondria in MAFLD pathogenesis.
• To discuss novel therapeutic strategies targeting this interplay for MAFLD treatment.

Main Methods:

• Literature review of studies on gut microbiota, metabolites, and MAFLD.
• Analysis of the mechanisms linking gut microbiota to liver mitochondria.
• Synthesis of current research on prebiotics, probiotics, and metabolites for MAFLD.

Main Results:

• Gut microbiota alterations, including changes in short-chain fatty acids and bile acids, impact hepatic homeostasis.
• Mitochondrial dysfunction is a critical component in MAFLD, influenced by gut-derived metabolites.
• The gut microbiota-mitochondria axis presents a promising therapeutic target for MAFLD.

Conclusions:

• Modulating the gut microbiota and its metabolites can positively influence mitochondrial function.
• Innovative treatments focusing on the gut microbiota-mitochondria axis hold potential for improving MAFLD.
• Understanding this complex interplay is crucial for developing effective MAFLD therapies.